Skip to main content

Novonesis (Novozymes) B (NSISBC.XD)

DXE Basic Materials Chemicals - SpecialtyView data quality →
52.9Fair

ValueMarkers Composite Index

Top 42%#25,989 of 44,714
Slightly Overvalued

11% above intrinsic value ($60)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-1.44
High Risk
Altman
3.57
Safe
DCF Value
$60
Undervalued
ROIC
6.4%
Low
P/E
14.3
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Novonesis (Novozymes) B (NSISBC.XD) — VMCI valuation read

Novonesis (Novozymes) B sits at VMCI 53/100, with the Basic Materials sector median at 50. That 3-point spread is the first thing to note on NSISBC.XD: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on NSISBC.XD are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on NSISBC.XD: NSISBC.XD trades at 14.0x earnings, 22% below the Basic Materials median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Basic Materials median (10.0%). The Risk read: net debt to EBITDA of -0.2x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

NSISBC.XD fell 3.1% over the trailing 7 days, with a -23.7% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in NSISBC.XD’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.